Effect of Pneumococcal Vaccination on Quality of Life in Children With Recurrent Acute Otitis Media: A Randomized, Controlled Trial

Quality of life of children and their caregivers during an AOM episode: development and use of a telephone questionnaire

“…The Family Functioning Questionnaire was developed to specifically assess the impact of recurrent AOM on the QOL of parents and families [10,11]. Four domains of the caregiver's life are covered (sleep deprivation, change of daily and social activities, emotional distress, cancelling family plans and trips), as well as two domains assessing adverse consequences for the siblings (feeling neglected and demanding extra attention).…”

“…Few instruments have been specifically designed to assess the impact of AOM on the QOL of children and their caregivers. Those available were used in face-to-face or postal surveys regarding recurrent otitis media or surgical interventions for chronic conditions [10-14]. Measurement of the severity of all AOM episodes and QOL consequences through telephone surveys is needed to assess the benefits of preventive interventions, including immunization programs against viral and bacterial infections.…”

Acute otitis media in children

“…Administering 7-valent PCV in older children with a history of AOM appears to have no benefit in preventing further episodes 17. In children 1–7 years of age this does not change the rate of recurrent AOM 18. It is not clear if administration of influenza vaccine to children does or does not reduce occurrence of AOM 19–21.…”

La vacuna neumocócica conjugada heptavalente (Prevenar™): Diferencias en su efectividad en distintas poblaciones

“…Varios ensayos más han evaluado la eficacia de la VNC7v sola o seguida de la vacuna neumocócica polisacárida en la prevención de recurrencia de la otitis media aguda, encontrando ausencia de eficacia 67 o un efecto preventivo discreto [68][69][70] .…”

“…En resumen, los ensayos aleatorizados de la VNC7v, así como los de la vacuna ampliada nonavalente, demuestran que es altamente eficaz frente a ENI por serotipos vacunales 2-3,47,71-72 , de moderada eficacia frente a la neumonía 47,65,72 , y algo eficaz frente a la otitis media aguda 2,12,[67][68][69][70]73 .…”